Table 2.
Results of Logistic Regression of Likelihood of Abandonment of Newly Initiated Oral Oncolytic Claims
| Independent Variable | Odds Ratio | 95% CI | P |
|---|---|---|---|
| Age group, years (reference, 0-40) | |||
| 41-65 | 0.82 | 0.55 to 1.23 | .346 |
| 65-80 | 0.71 | 0.47 to 1.07 | .102 |
| > 81 | 0.80 | 0.52 to 1.23 | .313 |
| Sex (reference, female) | |||
| Male | 0.99 | 0.86 to 1.14 | .899 |
| Annual household income (reference, > $75,000) | |||
| < $40,000 | 1.19 | 0.99 to 1.41 | .058 |
| $40,000-$75,000 | 1.13 | 0.96 to 1.32 | .142 |
| Geographic region (reference, Midwest) | |||
| Northeast | 1.15 | 0.95 to 1.38 | .157 |
| South | 0.91 | 0.76 to 1.08 | .279 |
| West | 1.01 | 0.81 to 1.25 | .937 |
| Patient cost-sharing amount (reference, $0-$100) | |||
| $101-$150 | 1.84 | 1.23 to 2.75 | .003 |
| $151-$200 | 1.51 | 0.97 to 2.34 | .066 |
| $201-$250 | 2.30 | 1.31 to 4.04 | .004 |
| $251-$350 | 2.31 | 1.59 to 3.36 | < .001 |
| $351-$500 | 3.28 | 2.20 to 4.88 | < .001 |
| > $500 | 4.46 | 3.80 to 5.22 | < .001 |
| Prescription activity, No. of claims (reference, 0) | |||
| 1 | 1.02 | 0.80 to 1.30 | .870 |
| 2-3 | 1.26 | 1.03 to 1.53 | .023 |
| 4-5 | 1.27 | 1.02 to 1.57 | .029 |
| > 5 | 1.50 | 1.24 to 1.81 | < .001 |
| Study drug (reference, capecitabine) | |||
| Imatinib | 2.09 | 1.68 to 2.60 | < .001 |
| Sorafenib | 4.87 | 3.74 to 6.34 | < .001 |
| Lenalidomide | 1.04 | 0.79 to 1.38 | .759 |
| Sunitinib | 1.63 | 1.21 to 2.21 | .001 |
| Erlotinib | 1.47 | 1.20 to 1.81 | < .001 |
| Temozolomide | 1.11 | 0.85 to 1.47 | .445 |
| Lapatinib | 2.15 | 1.39 to 3.33 | .001 |
NOTE. Psuedo R2 = 0.0922.